<DOC>
	<DOCNO>NCT02382419</DOCNO>
	<brief_summary>This randomized phase II trial study well carrageenan-containing gel ( vaginal gel ) work reduce rate human papilloma virus ( HPV ) infection healthy participant . Carrageenans , naturally derive seaweed , enhancements natural lubrication may effective block HPV infection .</brief_summary>
	<brief_title>Carrageenan-Containing Gel Reducing Rate HPV Infection Healthy Participants</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To measure overall efficacy intervention reduce rate incident cervical HPV infection . SECONDARY OBJECTIVES : I . Perform vitro exploratory test long vaginal application drug retain biological activity collect cervicovaginal lavage ( CVL ) different time spike sample HPV pseudovirions ( PsVs ) measure PsV entry target cell . II . These study expand test multiple HPV type examine whether anti-HPV activity intervention preserve set semen . III . Store swab potentially test candidate biomarkers microbicide efficacy safety . OUTLINE : Participants randomize 1 2 arm . ARM I : Participants apply carrageenan-containing gel vaginally within 12 hour prior vaginal sex act soon possible within 12 hour vaginal sex act use condoms 12 month . ARM II : Participants apply placebo gel vaginally within 12 hour prior vaginal sex act soon possible within 12 hour vaginal sex act use condoms 12 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Sexually active woman ethnicity race intact cervix eligible trial Engaging three intercourse event ( define penilevaginal intercourse ) per month ; subject must consent douche use vaginal product , include tampon , 24 hour enrollment study visit Normal Pap Atypical Squamous Cells Undetermined Significance ( ASCUS ) Pap test HPV deoxyribonucleic acid ( DNA ) negative reflex test via Hybrid Capture 2 ( Digene Corp. , Gaithersburg , MD ) , standard clinical assay within clinically acceptable screen guideline ( American Cancer Society [ ACS ] /American Society Colposcopy Cervical Pathology [ ASCCP ] 2012 Screening Guidelines ) Using adequate method contraception least 3 month change remain contraception duration trial ; adequate method contraception define either hormonal base method ( except vaginal ring ) ; intrauterine device ( IUD ) ( insert least 30 day prior enrollment ) ; female sterilization ; sexual activity partner vasectomy Speaks either English Spanish , live near Bronx plan move next year , able sign consent complete questionnaire aid train personnel Prior use HPV vaccine Women vaccineeligible age range receive vaccine prior enrollment , offer HPV vaccination end study ; brief , interested efficacy intervention prevent HPV absence HPV vaccination , since woman worldwide might utilize intervention vaccinate ; include United States ( US ) woman vaccine `` catchup '' 1926 year old age group ( beyond age group eligible Vaccines Children fund vaccination ) far low ( &lt; 10 % ) vaccine uptake ; also include entire group US woman &gt; 26 year age ; moreover , include woman age develop country , need HPV prevention strategy , may never vaccinate ; note delay vaccination woman 1926 year age one year safe reasonable , since insufficient data establish recommendation universal vaccination age group conclude American Cancer Society expert panel , include Principal Investigator ( PI ) protocol , Dr. Mark Einstein ; anticipate intervention gel efficacious , HPV vaccinate woman would need studied similar future trial power analysis take account vaccine effectiveness well Any previous surgical excision cervical intraepithelial neoplasia ( CIN ) hysterectomy A serious , concomitant disorder , include active systemic infection require treatment Prior history current malignancy adequately treat skin cancer ( squamous cell cancer basal cell carcinoma ) Documented suspected immunosuppressive disorder autoimmune disease Any significant cardiac , hepatic renal disease Pregnant and/or breastfeed Recent ( within 4 week screen ) concomitant long term treatment systemic steroid , immunosuppressive/immunomodulating drug ( e.g . cyclosporine , corticosteroid ) Intranasal , inhale and/or topical steroid permissible Documented human immunodeficiency virus ( HIV ) infection , genital wart , chancroid , pelvic inflammatory disease require long term treatment Active genital ulcer Use investigational drug 3 month prior screen must agree participate drug device study enrol study Any known allergy hypersensitivity vaginal lubricant component study product</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>